Of note, tirzepatide is a novel dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) approved in the USA for the treatment of T2DM [16]. Here, GLP1R is linked to type 2 diabetes mellitus.